Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414

A. M. Evens; K. R. Carson; J. Kolesar; C. Nabhan; I. Helenowski; N. Islam; B. Jovanovic; P. M. Barr; P. F. Caimi; S. A. Gregory; L. I. Gordon

doi:10.1093/annonc/mdu179

Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414

A. M. Evens, K. R. Carson, J. Kolesar, C. Nabhan, I. Helenowski, N. Islam, B. Jovanovic, P. M. Barr, P. F. Caimi, S. A. Gregory, L. I. Gordon

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1449
Number of pages	1
Journal	Annals of Oncology
Volume	25
Issue number	7
DOIs	https://doi.org/10.1093/annonc/mdu179
State	Published - Jul 2014
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hematology
Oncology

Access to Document

10.1093/annonc/mdu179

Cite this

Evens, A. M., Carson, K. R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P. M., Caimi, P. F., Gregory, S. A., & Gordon, L. I. (2014). Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414. Annals of Oncology, 25(7), 1449. https://doi.org/10.1093/annonc/mdu179

@article{df2f2a4f44fb46e3b0e6ea7643baa32d,

title = "Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414",

author = "Evens, {A. M.} and Carson, {K. R.} and J. Kolesar and C. Nabhan and I. Helenowski and N. Islam and B. Jovanovic and Barr, {P. M.} and Caimi, {P. F.} and Gregory, {S. A.} and Gordon, {L. I.}",

year = "2014",

month = jul,

doi = "10.1093/annonc/mdu179",

language = "English (US)",

volume = "25",

pages = "1449",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "7",

}

Evens, AM, Carson, KR, Kolesar, J, Nabhan, C, Helenowski, I, Islam, N, Jovanovic, B, Barr, PM, Caimi, PF, Gregory, SA & Gordon, LI 2014, 'Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414', Annals of Oncology, vol. 25, no. 7, pp. 1449. https://doi.org/10.1093/annonc/mdu179

Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414. / Evens, A. M.; Carson, K. R.; Kolesar, J. et al.
In: Annals of Oncology, Vol. 25, No. 7, 07.2014, p. 1449.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi

T2 - 10.1093/annonc/mdt414

AU - Evens, A. M.

AU - Carson, K. R.

AU - Kolesar, J.

AU - Nabhan, C.

AU - Helenowski, I.

AU - Islam, N.

AU - Jovanovic, B.

AU - Barr, P. M.

AU - Caimi, P. F.

AU - Gregory, S. A.

AU - Gordon, L. I.

PY - 2014/7

Y1 - 2014/7

UR - http://www.scopus.com/inward/record.url?scp=84903732070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903732070&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu179

DO - 10.1093/annonc/mdu179

M3 - Comment/debate

AN - SCOPUS:84903732070

SN - 0923-7534

VL - 25

SP - 1449

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this